Biogen Idec, Inc. Company Profile | BIIB Company Information

sucujovide.wordpress.com
Biogen Idec creates new standards of care in therapeuti areas with high unmetmedical needs. Founded in 1978, Biogen Idec is a globapl leader inthe discovery, development, manufacturinf and commercialization of innovativer therapies. Patients in more than 90 countriexs benefit fromBiogen Idec's significant productzs that address diseases such as multiple sclerosis (MS), lymphomz and rheumatoid arthritis. In 2008, Biogen Idec'sa total revenues grew 29 percent over 2007to $4.1 Currently, the company markets three major therapies and its producy development pipeline includes 20 products in Phase 2 clinicapl trials and beyond.
Our major products includew TYSABRI (natalizumab), the most recently approvedc treatment for relapsing formsof MS; AVONEX (Interferon beta-1a), the No. 1 prescribec therapy for relapsing forms of MS andRITUXAN (rituximab), the world's most prescribesd therapy for non-Hodgkin's lymphoma and marketed for the firstt time in 2006 for rheumatoid AVONEX and RITUXAN have for years rankedx among the top 10 biotechnology productws sold globally.
In recent years, we also have leveragec our core capabilities to expand developmengt into promising new therapeutic such as cardiovascular disease and Biogen Idec is headquarteredin Cambridge, Massachusetts, with internationalp headquarters in Zug, Switzerland. We have additionalo offices inthe U.S., Canada, Japan and throughout Europe. ...